OBJECTIVE: Most women with moderate to severe vasomotor symptoms (VMS) are untreated. This retrospective matched-cohort study aims to evaluate the healthcare resource utilization, work loss, and cost burden associated with untreated VMS. METHODS: Health insurance claims (1999-2011) were used to match (1:1) women with untreated VMS with control women using propensity score. Healthcare resource utilization, work productivity loss (disability + medically related absenteeism), and associated costs were compared between cohorts. RESULTS: During the 12-month follow-up, women with untreated VMS (n = 252,273; mean age, 56 y) had significantly higher healthcare resource utilization than women in the control cohort: 82% higher for all-cause outpatient visits (95% CI, 81-83; P < 0.001) and 121% higher (95% CI, 118-124; P < 0.001) for VMS-related outpatient visits. Mean direct costs per patient per year were significantly higher for VMS women (direct cost difference, US$1,346; 95% CI, 1,249-1,449; P < 0.001). VMS women had 57% (95% CI, 51-63; P < 0.001) more indirect work productivity loss days than controls, corresponding to an incremental indirect cost per patient per year associated with untreated VMS of US$770 (95% CI, 726-816; P < 0.001). CONCLUSIONS: This study shows that untreated VMS are associated with significantly higher frequency of outpatient visits and incremental direct and indirect costs.
OBJECTIVE: Most women with moderate to severe vasomotor symptoms (VMS) are untreated. This retrospective matched-cohort study aims to evaluate the healthcare resource utilization, work loss, and cost burden associated with untreated VMS. METHODS: Health insurance claims (1999-2011) were used to match (1:1) women with untreated VMS with control women using propensity score. Healthcare resource utilization, work productivity loss (disability + medically related absenteeism), and associated costs were compared between cohorts. RESULTS: During the 12-month follow-up, women with untreated VMS (n = 252,273; mean age, 56 y) had significantly higher healthcare resource utilization than women in the control cohort: 82% higher for all-cause outpatient visits (95% CI, 81-83; P < 0.001) and 121% higher (95% CI, 118-124; P < 0.001) for VMS-related outpatient visits. Mean direct costs per patient per year were significantly higher for VMS women (direct cost difference, US$1,346; 95% CI, 1,249-1,449; P < 0.001). VMS women had 57% (95% CI, 51-63; P < 0.001) more indirect work productivity loss days than controls, corresponding to an incremental indirect cost per patient per year associated with untreated VMS of US$770 (95% CI, 726-816; P < 0.001). CONCLUSIONS: This study shows that untreated VMS are associated with significantly higher frequency of outpatient visits and incremental direct and indirect costs.
Authors: Ellen B Gold; Sybil L Crawford; Janie F Shelton; Ping G Tepper; Carolyn J Crandall; Gail A Greendale; Karen A Matthews; Rebecca C Thurston; Nancy E Avis Journal: Menopause Date: 2017-01 Impact factor: 2.953
Authors: JoAnn E Manson; Aaron K Aragaki; Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Rowan T Chlebowski; Barbara V Howard; Cynthia A Thomson; Karen L Margolis; Cora E Lewis; Marcia L Stefanick; Rebecca D Jackson; Karen C Johnson; Lisa W Martin; Sally A Shumaker; Mark A Espeland; Jean Wactawski-Wende Journal: JAMA Date: 2017-09-12 Impact factor: 56.272
Authors: Annlouise R Assaf; Andrew G Bushmakin; Nina Joyce; Michael J Louie; Michael Flores; Margaret Moffatt Journal: Am Health Drug Benefits Date: 2017-09
Authors: Dahima Cintron; Melissa Lipford; Laura Larrea-Mantilla; Gabriela Spencer-Bonilla; Robin Lloyd; Michael R Gionfriddo; Shalak Gunjal; Ann M Farrell; Virginia M Miller; Mohammad Hassan Murad Journal: Endocrine Date: 2016-08-11 Impact factor: 3.633
Authors: Ekta Kapoor; Madison Okuno; Virginia M Miller; Liliana Gazzuola Rocca; Walter A Rocca; Juliana M Kling; Carol L Kuhle; Kristin C Mara; Felicity T Enders; Stephanie S Faubion Journal: Maturitas Date: 2020-10-14 Impact factor: 4.342